Twist Bioscience CEO sells 31,348 shares to cover taxes
Rhea-AI Filing Summary
Insider sale to cover tax withholding following PSU vesting. The Form 4 shows Twist Bioscience Corp (TWST) Chief Executive Officer and Director Emily M. Leproust reported a sale of 31,348 shares on 10/06/2025 at a price of $32.187 per share. The filing states the sale was a mandated "sell to cover" to satisfy tax-withholding obligations tied to vesting Performance Stock Units, not a discretionary trade. After the transaction, the Reporting Person beneficially owns 601,212 shares and holds multiple outstanding employee stock options totaling reported option counts, including 64,950 exercisable shares from a performance grant.
Positive
- Sale was a mandatory "sell to cover" tied to PSU tax withholding, not a discretionary trade
- Substantial remaining ownership: reporting person retains 601,212 shares after the transaction
- Existing vested options: holds 64,950 exercisable shares from a performance grant
Negative
- Immediate dilution risk: sale of 31,348 shares increased current free float by that amount
- Potential future share supply: multiple outstanding options 600,000 reported in tables) could be exercised over time
Insights
Mandatory sell-to-cover after PSU vesting reduced holdings by 31,348 shares.
The sale is described as required by the issuer's election under its equity plans to satisfy tax withholding for vested Performance Stock Units, which means the transaction is an administrative liquidity event rather than a discretionary sale.
The reporting shows continued substantial ownership of 601,212 shares and several outstanding options, including 64,950 vested performance options; monitor future scheduled vesting or option exercises over the next 12 months for additional share supply.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 31,348 | $32.187 | $1.01M |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
